Welcome to our dedicated page for Akari Therapeutics news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics stock.
Akari Therapeutics plc develops oncology antibody-drug conjugates built around RNA splicing modulator payloads. News about AKTX centers on its ADC platform, the PH1 payload technology, and lead program AKTX-101, a TROP2-targeted ADC studied in solid tumor models including bladder, lung and breast cancer. Updates also cover intellectual-property protection for the company’s payload chemistry and therapeutic applications.
Recurring company developments include preclinical data releases, oncology conference abstracts, strategic development collaborations, capital-structure disclosures, governance matters, and American Depositary Share program updates. As an ADR issuer, Akari’s news may also address ordinary-share and ADS mechanics tied to Nasdaq listing requirements and shareholder approvals.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Akari Therapeutics, Plc (Nasdaq: AKTX) announced it has been granted an additional 180-day compliance period by Nasdaq, extending the deadline to regain compliance with the minimum bid price requirement until October 23, 2023. To maintain its listing, Akari must keep a minimum closing bid price of $1.00 per share for at least ten consecutive business days. There is no immediate impact on the company’s Nasdaq listing, and its American Depository Shares will continue to be traded. Akari is focused on developing advanced therapies for autoimmune diseases, with lead investigational asset nomacopan undergoing Phase 3 trials for pediatric HSCT-TMA. The company holds Orphan Drug and Fast Track designations from the FDA for this treatment.